Clinical effect of recombinant human endostatin combined with three dimensional conformal radiotherapy on treatment of local advanced non-small cell lung cancer
10.7619/jcmp.201416021
- VernacularTitle:重组人血管内皮抑制素联合三维适形放疗治疗局部晚期非小细胞肺癌的临床疗效
- Author:
Rongqiang LIU
1
;
Shufang ZHANG
Author Information
1. 福建医科大学附属南平市第一医院 放疗科
- Keywords:
recombinant human endostatin;
three dimensional conformal radiotherapy;
non-small cell lung cancer;
survival time;
radioactive lung injurl
- From:
Journal of Clinical Medicine in Practice
2014;(16):75-77
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of recombinant human endostatin (en-dostar)combined with three dimensional conformal radiotherapy (3D-CRT)on treatment of patients with non-small cell lung cancer (NSCLC).Methods 78 patients with NSCLC in phase ⅢA ~ⅢB by histopathology and cytology were randomly divided into control group (treated with single 3D-CRT) and experiment group (treated with endostar and 3D-CRT),39 cases in each group.Clinical efficacy and adverse responses were evaluated after two cycles of treatment and survival time was observed until the end of follow-up.Results The objective remission rate (RR)and disease control rate (DCR)in experiment group were 69.2% and 89.7% respectively,which were evidently higher than the 33.3%and 71.8% in control group (P <0.05 or P <0.01).The main adverse responses in both groups were anemia,nausea and vomiting,leukopenia and radioactive lung injury and all were tolerable.Until the end of follow-up,the medium progression free survival time and medium survival time in experimental group were 8 and 13 months,and in control group were 5 and 9 months respectively.Conclusion Endostar combined with 3D-CRT are superior to single 3D-CRT without increasing adverse responses in the treatment of NSCLC.
